Diligence memo · auto-generated · as of July 2, 2026

Volta Labs, Inc.

Volta Labs, Inc. looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Volta Labs, Inc. operates in Biotech, based in BOSTON, MA, USA. Unlocking the utility of genomics for the world.

Sub-sector tags: Biotechnology, Genomics, Hard Tech, Hardware, Robotics, biotech, energy.

Capital & rounds (filed)filed

Volta Labs, Inc. has raised $38M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $25M on 2022-01-27.

Most recent recorded round closed around 2023-12-29.

Valuation (modeled)modeled

Provath models Volta Labs, Inc. at approximately $112M (range $25M–$222M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.73× the median modeled value of Series B Biotech companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 12 months.

Last raise 2.5 yr ago; this sector typically re-raises about every 11 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 3.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 95% of Biotech peers (233 compared).

Modeled value ranks above 89% of those peers.

Closest niche peers: Watchmaker Genomics, Inc., Mytos, Inc., ZBiotics Co, Siren Biotechnology, Inc., Invert, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.